← board
VRDN
Viridian Therapeutics, Inc.distress 5/10 · elevated risk$19.02-1%today-44% from 52w high
Lead: Thyroid Eye Disease
Revenue
pre-revenue
Liquidity
$321M
Runway
1.1 yrs
Shares 1y
+26%
Price & events
-40.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
+5.5%
1W
+10.1%
1M
+33.7%
3M
-42.2%
6M
+6.0%
1Y
+21.8%
2Y
+10.6%
5Y
+10.6%
All
Overview
- Market Cap
- $1.96B
- Enterprise Value
- $1.81B
- Volume
- 81.11K
- 52 Week Range
- $13.30 – $33.78
- Total Shares
- 103.07M
- Float Shares
- 97.76M
- Short %
- 16.29%
- % Held by Insiders
- 0.14%
- % Held by Institutions
- 111.51%
- RVOL
- 0.04x
- Beta
- 0.90
Pipeline stages · 1 programs
VRDN-003
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-01 | Phase 3 | VRDN-003 | Thyroid Eye Disease | — | active not recruiting |
Catalyst news & presentations · 16
- Q1 2027Guided 70%regulatory submissionFiled (NDA/BLA)elegrobart · BLA submission to FDASEC 8-K
- second half of 2026Guided 55%readoutPhase 1VRDN-008 · Proof-of-concept IgG reduction data in healthy volunteersSEC 8-K
- year-end 2026Guided 40%regulatory submissionFiled (NDA/BLA)VRDN-003 · BLA submissionSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 3VRDN-003 · Topline data from REVEAL-1 and REVEAL-2 trials for VRDN-003SEC 8-K
- June 30, 2026PDUFAPDUFAveligrotug · PDUFA target action date for veligrotug BLASEC 8-K
- Q2 2026readoutPhase 3elegrobart · Topline data from REVEAL-2 phase 3 trialSEC 8-K
- 2H 2025regulatory submissionFiled (NDA/BLA)VRDN-001 · BLA submission for VRDN-001SEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)veligrotug · BLA submission for veligrotug for TEDSEC 8-K
- second half of 2025readoutPhase 1VRDN-006 · Proof-of-concept IgG reduction data in healthy volunteersSEC 8-K
- 2025-07-30partnershipveligrotug, VRDN-003 · Exclusive license to develop/commercialize veligrotug and VRDN-003 in Japan; $70M upfront, $315M milestones, tiered royalties.SEC 8-K
- Year-end 2024readoutPhase 3VRDN-001 · Topline data from THRIVE-2 trial in chronic TEDSEC 8-K
- by year-end 2024regulatory submissionFiled (NDA/BLA)VRDN-006 · IND submission for VRDN-006SEC 8-K
- December 2024readoutPhase 3veligrotug · Topline data from THRIVE-2 phase 3 trialSEC 8-K
- Sept. 2024readoutPhase 3VRDN-001 · Topline data from THRIVE trial in active TEDSEC 8-K
- Aug. 2024trial initiationsecondaryPhase 3VRDN-003 · Initiation of Phase 3 REVEAL-1 and REVEAL-2 trialsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $36 (+90% upside) · 16 analysts
- 2026-06-30NeedhamBuy
- 2026-06-30WedbushOutperform
- 2026-06-30RBC CapitalOutperform
- 2026-06-30Truist SecuritiesBuy
- 2026-06-29Wells FargoEqual-Weight → Overweight
- 2026-06-29NeedhamBuy
Competitors — Thyroid Eye Disease
Recent news
- 2026-07-21Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
- 2026-07-20Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary - Quartr
- 2026-07-18VRDN Stock Records Biggest Single Day Gains In 45 Months – And It’s Not Just Due To A Better-Than-Feared Q1 Loss - Stocktwits
- 2026-07-15Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
- 2026-07-15Viridian Metals Commences Trading on the OTCQB Venture Market Under the Symbol “VIRMF” - GlobeNewswire
- 2026-07-15Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich? - Yahoo Finance
- 2026-07-15Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today - Yahoo Finance
- 2026-07-14Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.